drug
SACUBITRIL AND VALSARTAN
Marketedupdated 3mo agoby Somerset Therapeutics LLC
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 8- tagApproval4 co-mentions · 1 sources
- tagSmall Molecule2 co-mentions · 1 sources
- drugvalsartan2 co-mentions · 1 sources
- drugDiovan2 co-mentions · 1 sources
- companyShenzhen Salubris Pharmaceuticals Co Ltd1 co-mentions · 1 sources
- tagCardiology1 co-mentions · 1 sources
- tagHypertension1 co-mentions · 1 sources
- drugNorvasc1 co-mentions · 1 sources
all catalysts(1)
Trials studying SACUBITRIL AND VALSARTAN
- phase2A Proof of Concept and Dose-finding Study of XXB750 in Patients With Heart Failure
- phase3Phase 3 Trial to Evaluate the Efficacy and Safety of CKD-202A
- phase4Efficacy and Safety of Sacubitril/Valsartan Compared With Enalapril on Morbidity, Mortality, and NT-proBNP Change in Patients With CCC
- phase3A Safety Study of Sacubitril/Valsartan in Japanese Pediatric Patients With Heart Failure Due to Systemic Left Ventricle Systolic Dysfunction Who Have Completed CLCZ696B2319E1 Study
- phase3Open-label Extension Study to Evaluate Long-term Safety of Sacubitril/Valsartan in Pediatric Patients With HF
- phase1Bioequivalence Study to Compare Sacubitril and Valsartan Tablets (97mg/103mg) Versus Entresto® (Sacubitril and Valsartan) Tablets (97 mg/103 mg)
- phase3Changes in NT-proBNP, Safety, and Tolerability in HFpEF Patients With a WHF Event (HFpEF Decompensation) Who Have Been Stabilized and Initiated at the Time of or Within 30 Days Post-decompensation (PARAGLIDE-HF)
- phase2Prevention of Cardiac Dysfunction During Breast Cancer Therapy
Patent cliff
source: FDA Orange Bookfirst barrier falls
Nov 8, 2026
89 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (6)
- Feb 2, 2037formulationUS 10722471
- Feb 2, 2037formulationUS 10722471
- May 27, 2027compositionUS 8877938289d
- May 27, 2027compositionUS 8877938289d
- Nov 8, 2026method-of-use (U-1723)US 938813489d
- Nov 8, 2026method-of-use (U-1723)US 938813489d
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that